Drug Trial Radar · NCT00864383
Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis
Last checked: Nov 20, 2026Latest source record: Mar 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,931
Actual
Start
Jan 2008
Primary completion
Oct 2013
Study completion Feb 2014
Sponsor
- Lead sponsor
- Global Alliance for TB Drug DevelopmentAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- European and Developing Countries Clinical Trials Partnership (EDCTP); University College, London; Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma; Sanofi
- First posted
- Mar 18, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
REMoxTB is a study for the "Rapid Evaluation of Moxifloxacin in the treatment of sputum smear positive tuberculosis". REMoxTB aims to find and evaluate new drugs and regimens that shorten the duration of tuberculosis therapy. The purpose of REMoxTB is to evaluate the efficacy, safety and acceptability of two moxifloxacin-containing treatment combinations to determine whether substituting ethambutol with moxifloxacin in one combination, and/or substituting isoniazid with moxifloxacin in another combination, makes it possible to reduce the duration of treatment for TB.
Conditions
- Pulmonary Tuberculosis
Interventions
Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & RifampicinDrug
Moxifloxacin 400 mg Rifampicin \< 45 kg 450 mg \> 45 kg 600 mg Isoniazid 300 mg Pyrazinamide \< 40 kg 25 mg/kg rounded to nearest 500 mg\* 40-55 kg 1000 mg \> 55 kg - 75 kg 1500 mg \> 75 kg 2000 mg Ethambutol \< 40 kg 15 mg/kg rounded to nearest 100 mg 40-55 kg 800 mg \> 55 kg - 75 kg 1200 mg \> 75 kg 1600 mg \*For pyrazinamide dosing in patients \< 40 kg, 1000 mg used instead of 500 mg All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Combined Failure of Bacteriological Cure and Relapse Within One Year of Completion of Therapy as Defined by Culture Using Solid Media (Lowenstein-Jensen - LJ).Time frame: 18 months (within one year of completion of therapy)
- Number of Patients With Grade 3 or 4 Adverse Events (Using a Modified Division of Acquired Immunodeficiency Syndrome National Institute of Allergy and Infectious Diseases [DAIDS] Scale of Adverse Event Reporting)Time frame: 18 months (within one year of completion of therapy)
Locations
47 sites in 9 countries. Site status is shown where the registry gives one.
Beijing Tuberculosis and Thoracic Tumor Research Institute
Beijing, China
Shanghai Pulmonary Hospital
Shanghai, China
TB Institute
Tianjin, China
A-One Hospital
Delhi, India
Dr. D.K. Chauhan
New Delhi, India
Centre for advanced lung and sleep disorders
New Delhi, India
Dr. Mittal's clinic
New Delhi, India
Diligent Hospital
New Delhi, India
Ish Medical Centre and Respiratory Lab,
New Delhi, India
Smt Prakash Devi Memorial Medical Centre,
New Delhi, India
Nirmal Kumar Jain
Jaipur, Rajasthan, India
Mahatma Gandhi Medical College& Hospital
Jaipur, Rajsthan, India
Ram-Tej Hospital,
Agra, Uttar Pradesh, India
Siddharth Nursing Home,
Agra, Uttar Pradesh, India
Rajul Nursing Home
Aligarh, Uttar Pradesh, India
Varshneya Chest Clinic & Eye Care Centre
Aligarh, Uttar Pradesh, India
Dr. Neeraj Gupta Clinic
Firozabad, Uttar Pradesh, India
S.P.S Chauhan Clinic
Firozabad, Uttar Pradesh, India
Dr. R. K. Garg's Clinic,
Ghaziabad, Uttar Pradesh, India
Indra Nursing Home and Maternity Centre
Ghaziabad, Uttar Pradesh, India
Dr. AK Singh Clinic
Kanpur, Uttar Pradesh, India
Dr. S. K. Katiyar, Swaroop Nagar,
Kanpur, Uttar Pradesh, India
Guru Tej Bahadur Hospital
Kanpur, Uttar Pradesh, India
Dr. Komal Gupta
Lucknow, Uttar Pradesh, India
New City Hospital and Trauma Centre,
Lucknow, Uttar Pradesh, India
Surya Chest Foundation,
Lucknow, Uttar Pradesh, India
Surya Kant Clinic
Lucknow, Uttar Pradesh, India
Arya Chest Clinic, UP,India
Meerut, Uttar Pradesh, India
Dr. Mahip Saluja Clinic, U.P.
Meerut, Uttar Pradesh, India
Dr. S. P. Sondhi Clinic,
Meerut, Uttar Pradesh, India
Sri Ram Plaza
Meerut, Uttar Pradesh, India
Jigyasa Medical Center
Morādābād, Uttar Pradesh, India
Saanvi MultiSpeciality Clinic,
Morādābād, Uttar Pradesh, India
Centre for Respiratory Disease Research at KEMRI
Nairobi, Kenya
Institute of Respiratory Medicine (IPR) Jalan Pahang
Kuala Lumpur, Malaysia
Hospital General de Occidente de la secretaria
Guadalajara, Seattle, Mexico
Centre for TB Research and Innovation, University of Cape Town Lung Institute
Cape Town, South Africa
Tiervlei Trial Center and University of Stellenbosch
Cape Town, South Africa
Unit for Clinical & Biomedical TB Research, MRC Durban
Durban, South Africa
Madibeng centre for Research, 40 Pienaar Street,
Madibeng, Brits, South Africa
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.